THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

Conditions

• Resectable Hepatocellular Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ateganosine — DRUG
  ateganosine: 180 mg IV D1, D2, D3 of 21-day cycle
• Cadonilimab — DRUG
  cadonilimab: 10 mg/kg IV D5 of 21-day cycle

Study Details

The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).

Key Dates

First listed

Mar 3, 2026

Start date

Sep 1, 2026

Status verified

Sep 2026

Primary completion

Sep 1, 2029

Completion

Sep 1, 2030

Study Design

Enrollment

60 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm A: Ateganocine + Cadonilimab
  Ateganosine: 60 mg/day (180 mg/cycle) IV over 30 minutes±5 minutes Cadonilimab: 10 mg/kg IV over 60 minutes±5 minutes
• Experimental: Arm B: Ateganocine
  Ateganosine: 60 mg/day (180 mg/cycle) IV over 30 minutes±5 minutes
• Experimental: Arm C: Cadonilimab
  Cadonilimab: 10 mg/kg IV over 60 minutes±5 minutes

Primary Outcome Measure

Incidence of treatment-related delay of surgical resection >28 days from expected surgery date. [ Time Frame: 28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms) ]

Central Contacts

• Carrie Manwaring
  214-648-7097
  [email protected]

Locations (1)

Find similar trials in Dallas, TX